Skip navigation

Sanofi wins diabetes drug approval in Japan

PARIS (Reuters) - French drugmaker Sanofi said it won approval from the Japanese government for its Lyxumia drug for the treatment of Type 2 diabetes in combination with basal insulin. Full story

Type 1 diabetes vaccine shows promise in early study: researchers

CHICAGO (Reuters) - An early stage study suggests an experimental vaccine may be able to tame bits of the immune system that go haywire in people with type 1 diabetes, offering hope for a new way to delay or prevent the autoimmune disease, researchers said on Wednesday. Full story

Sanofi's next-generation insulin shows edge over Lantus

PARIS (Reuters) - An improved version of Sanofi's blockbuster insulin Lantus is better than the older drug at controlling blood sugar lows at night, a common side effect in diabetics treated with insulin, according two late-stage tests published on Saturday. Full story

Medtronic takes 'first step' toward U.S. sale of artificial pancreas

CHICAGO (Reuters) - Type 1 diabetics, who run the risk of dangerously low blood sugar, may be a step closer to getting help from a crude artificial pancreas device that can read blood sugar levels and automatically turn off the flow of insulin after a clinical trial showed the device is safe. Full story

Lilly to take over development of diabetes drug

Eli Lilly and Co. will pay Canadian drug developer Transition Therapeutics Inc. $7 million and take over the development of a potential diabetes treatment heading into mid-stage clinical testing. Full story

Sanofi steps up diabetes drive as rivals raise the stakes

FRANKFURT (Reuters) - In a leafy suburb of Frankfurt, a state-of-the-art plant churns out up to 1 million insulin pens every day in French drugmaker Sanofi's drive to keep its no. 2 spot in the $43 billion-a-year diabetes market. Full story

Sponsored Links

Articles

Marijuana tied to better blood sugar control

Novo Nordisk says completes hemophilia drug trial

Could Marijuana Reduce Diabetes Risk?

U.S. launch of Novo's new insulin faces long delay

Shaped Like an Apple? Beware Kidney Disease

Why Snacking at Night Is Bad For You

Novo to sell Tresiba in Europe at 60-70 percent premium over Lantus

Test strip supply linked to better diabetes care

Insulin-requiring diabetes up in young children: study

Type 1 diabetes rising in kids - study

Video

  Marijuana: the new diet drug?

A new study published in The American Journal of Medicine finds marijuana smokers have better insulin control and smaller waists. MSNBC’s Lawrence O’Donnell discusses the study with Dr. Murray Mittleman of the Harvard School of Public Health, one of the co-authors of the study.

  Claire McCaskill on getting healthy: I didn't want insulin shots

In Mika Brzezinski's latest book "Obsessed," Sen. Claire McCaskill, D-Mo., tells her story of a life-changing moment where she knew she needed to improve her physical health. Sen. McCaskill joins Morning Joe to discuss her weight-loss journey.

  Hispanics may face higher risk for diabetes

A new study says Hispanics are more likely to store fat in their pancreas, but less likely to be able to produce more insulin to compensate for this excess fat, putting them at higher risk for type 2 diabetes. KVEO's Michael Lopez reports.

  Saving cash and saving lives

Naomi Wyatt of the Camden Coalition of Health Care Providers joins The Dylan Ratigan Show to talk about hot-spotting in health care.

  New treatment for Alzheimer’s ‘promising’

A promising study funded by the National Institutes of Health found that a spritz of insulin may improve memory in Alzheimer’s patients. NBC’s Robert Bazell has more.

advertisement | ad info

Related Photos

A diabetic patient displays her insulin supplies and blood sugar level-testing device at the J.W.C.H. safety-net clinic in the center of skid row in downtown Los Angeles
A diabetic patient displays her insulin supplies and blood sugar level-testing device at the J.W.C.H. safety-net clinic in the center of skid row in downtown Los Angeles

A diabetic patient displays her insulin supplies and blood sugar level-testing device at the J.W.C.H. safety-net clinic in the center of skid row in downtown Los Angeles, July 30, 2007. REUTERS/Lucy Nicholson

Handout shows an employee working on a Novo Nordisk production line for the new long-acting insulin Tresiba drug
Handout shows an employee working on a Novo Nordisk production line for the new long-acting insulin Tresiba drug

An employee works on a Novo Nordisk production line for the new long-acting insulin Tresiba drug, in this August 18, 2012 handout picture provided by Novo Nordisk. U.S. regulators on February 10, 2013 dealt a major blow to Novo Nordisk's hopes for its new long-acting insulin Tresiba by demanding the

Handout shows the new long-acting insulin Tresiba drug on a Novo Nordisk production line
Handout shows the new long-acting insulin Tresiba drug on a Novo Nordisk production line

The new long-acting insulin Tresiba drug is seen on a Novo Nordisk production line, in this 2012 handout picture provided by Novo Nordisk. U.S. regulators on February 10, 2013 dealt a major blow to Novo Nordisk's hopes for its new long-acting insulin Tresiba by demanding the Danish drugmaker conduct